Bangalore-based Biocon has secured approval from the Central Drugs Standard Control Organisation (CDSCO) for Liraglutide, a crucial diabetes drug. The approval includes both the drug substance and its injectable drug product (6 mg/ml solution in a pre-filled pen and cartridge), through its subsidiary Biocon Pharma.
This is the generic version of Victoza, a globally recognized treatment for type 2 diabetes in adults and children aged 10 and above.
The approval falls under the newly introduced 101 route, which allows India to recognize drugs already cleared by top global regulators like the USFDA and EMA—cutting red tape and getting meds to market faster.
What This Means for Everyday Indians
India has over 77 million people living with diabetes. That number is only climbing. Many can’t afford modern treatments like Victoza, which costs thousands per month out of pocket. Now, Biocon’s Liraglutide brings a much-needed affordable option.
“This is our first vertically integrated GLP-1 in India,” said Siddharth Mittal, CEO of Biocon. “It’s not just a drug launch. It’s a lifeline for millions.”
Let’s Be Real—This Is Long Overdue
India has the second-largest diabetic population in the world. And yet, drugs like Victoza stayed locked behind import prices and slow regulatory red tape. Biocon’s win isn’t just a business milestone—it’s a jab at the irony of a pharma-rich country still struggling with drug access.
Honestly, for a country making vaccines for the world, waiting this long for a Victoza generic is a bit like being the chef who can’t afford to eat at their own restaurant.
What’s Next?
Biocon plans a quick commercial rollout of Liraglutide in India through its local partners. Given the high demand, the launch is expected to make waves in the Indian pharma market—and more importantly, in Indian households.
Biocon, already a global player in biologics and complex generics, continues its mission to make essential meds more accessible. From cancer to diabetes, its portfolio is aimed at tackling diseases that affect everyday people, not just profit margins.
Also Read Biocon Poised to Dominate Diabetes-Obesity Space, Says Kiran Mazumdar-Shaw
